Nasdaq Stockholm

Kent NHS trusts in the UK to modernize patient diagnostics with Sectra in a multi-hospital collaborative environment

Retrieved on: 
Thursday, May 12, 2022
Magnetic resonance imaging, Nasdaq Stockholm, Google Images, International, AI, CT, Patient, Medway NHS Foundation Trust, Maidstone, Trauma, East Kent Hospitals University NHS Foundation Trust, SEK, RIS, X-ray, Efficiency, PACS, Program, Hospital, Workload, Radiology, Trust, Maidstone and Tunbridge Wells NHS Trust, Cancer, Diagnosis, NHS foundation trust, CEO, Medical imaging, Pharmaceutical industry, Sectra AB, Sectra AB

The new agreement will help a consortium of trusts deliver faster diagnoses, improve capacity and deliver community diagnostics.

Key Points: 
  • The new agreement will help a consortium of trusts deliver faster diagnoses, improve capacity and deliver community diagnostics.
  • Benefits from utilizing the same imaging system as many other trusts across large of South East England are also expected.
  • It will also support improved access to imaging across large parts of South East England, where many other hospitals also use the Sectra PACS.
  • The new system will also integrate into the Kent and Medway Breast Screening Service PACS, already provided by Sectra.

Utilization of authorization in Hexagon AB to repurchase own shares due to incentive programme

Retrieved on: 
Wednesday, May 11, 2022
Board, Hexagon AB, Social Security, Share repurchase, Annual, Board of directors, Sustainability, Renewable energy, Security (finance), Hexagon, Nasdaq Stockholm

The purpose of the repurchase is to ensure Hexagon's undertakings in respect of Share Programme 2022/2025 (other than delivery of shares to participants in the incentive programme), including covering social security costs.

Key Points: 
  • The purpose of the repurchase is to ensure Hexagon's undertakings in respect of Share Programme 2022/2025 (other than delivery of shares to participants in the incentive programme), including covering social security costs.
  • Acquisition may be made of maximum 5,500,000 Series B shares.
  • The total number of outstanding shares in Hexagon is 2,705,477,888 shares, including 110,250,000 shares of Series A and 2,595,227,888 shares of Series B.
  • In the event of a fully executed share repurchase, the company will own shares representing maximum 0.6 per cent of the shares issued in the company.

TF Bank: Monthly statistics April 2022

Retrieved on: 
Tuesday, May 10, 2022
Credit card, Solution, Automation, Nasdaq Stockholm

The information was provided for publication on May 10, 2022 at 08.30 CEST.

Key Points: 
  • The information was provided for publication on May 10, 2022 at 08.30 CEST.
  • TF Bank was founded 1987 and is an internet-based niche bank offering consumer banking services and e-commerce solutions through a proprietary IT platform with a high degree of automation.
  • Deposit and lending activities are conducted in Sweden, Finland, Norway, Denmark, Estonia, Latvia, Lithuania, Poland, Germany and Austria through branch or cross-border banking.
  • The operations are divided into three segments: Consumer Lending, Ecommerce Solutions and Credit Cards.

Unique Alfa Laval technology recovers industrial waste heat for reuse in Hamburg's district heating network

Retrieved on: 
Tuesday, May 10, 2022
Corrosion, Carbon, Nasdaq Stockholm, Alfa Laval, Water, Elbe, CO2, Heat, Food, SEK, Food & Water Watch, Aurubis, Industry, Goal, Technology, Natural Resources, Renewable energy, Recycling, Energy

LUND, Sweden, May 10, 2022 /PRNewswire/ --Alfa Laval's specially designed heat exchangers will recover waste heat from a sulphuric acid plant for reuse in district heating in Hamburg, Germany.

Key Points: 
  • LUND, Sweden, May 10, 2022 /PRNewswire/ --Alfa Laval's specially designed heat exchangers will recover waste heat from a sulphuric acid plant for reuse in district heating in Hamburg, Germany.
  • This collaboration resulted in a process based on unique Alfa Laval plate heat exchanger technology designed to meet these requirements.
  • Now Alfa Laval will supply heat exchangers for the next phase, with delivery scheduled for 2023 and 2024.
  • Did you know Alfa Laval's plate heat exchanger technology is 20-50 percent more efficient than conventional technology used by the industry.

Calliditas Therapeutics to participate in upcoming investor conferences

Retrieved on: 
Tuesday, May 10, 2022
Head, NOX, American depositary receipt, Nasdaq Stockholm, CET, EMA, Nasdaq, European Medicines Agency, Budesonide, LSX, FDA, Person, CALT, MAA, Marketing, Congress, Conference, Primary biliary cholangitis, Capsule, IPO, Therapy, Pharmaceutical industry, Citigroup

STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:

Key Points: 
  • STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:
    The 8thAnnual LSX World Congress on May 10-11, 2022 in London, United Kingdom
    The ABGSC Life Science Summit on May 18-19, 2022, in Stockholm, Sweden.
  • Management will be presenting and will host one-on-one investor meetings at the other three conferences.
  • To schedule a one-on-one meeting with Calliditas, please contact your representative at H.C Wainwright, Jefferies, or Citi.
  • Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Calliditas Therapeutics to participate in upcoming investor conferences

Retrieved on: 
Tuesday, May 10, 2022
Head, NOX, American depositary receipt, Nasdaq Stockholm, CET, EMA, Nasdaq, European Medicines Agency, Budesonide, LSX, FDA, Person, CALT, MAA, Marketing, Congress, Conference, Primary biliary cholangitis, Capsule, IPO, Therapy, Pharmaceutical industry, Citigroup

STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:

Key Points: 
  • STOCKHOLM, May 10, 2022 /PRNewswire/ --Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announcedthat itsmanagement team will participate in the following upcoming investor conferences and events:
    The 8thAnnual LSX World Congress on May 10-11, 2022 in London, United Kingdom
    The ABGSC Life Science Summit on May 18-19, 2022, in Stockholm, Sweden.
  • Management will be presenting and will host one-on-one investor meetings at the other three conferences.
  • To schedule a one-on-one meeting with Calliditas, please contact your representative at H.C Wainwright, Jefferies, or Citi.
  • Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway

Retrieved on: 
Tuesday, May 10, 2022
Development, University, Core, Biomarker, National Institute on Aging, Safety, Parkinson's disease, Caregiver, BAN2401, Pharmaceuticals and Medical Devices Agency, Person, Eisai, National, Medication, Ageing, CEO, Clarity, AD, Brain, CET, Patient, Partnership, Neurodegeneration, Clinical trial, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biologics license application, Disease, Research, Alzheimer's Research & Therapy, Medicines and Healthcare products Regulatory Agency, Priority review, AB, Commercialization, Nasdaq Stockholm, Degenerative disease, BLA, PMDA, National Institute, MCI, Prescription Drug User Fee Act, Nasdaq, Food, Amyloid, Biogen, ADAS, Marketing, PDUFA, Autumn, Pharmaceutical industry, Medical imaging, Medical device, EU, Alzheimer's disease, Uppsala University

While Eisai is currently submitting lecanemab under the accelerated approval pathway, the lecanemab Phase 3 confirmatory Clarity AD clinical trial conducted with 1,795 patients will report out in the Fall of 2022.

Key Points: 
  • While Eisai is currently submitting lecanemab under the accelerated approval pathway, the lecanemab Phase 3 confirmatory Clarity AD clinical trial conducted with 1,795 patients will report out in the Fall of 2022.
  • Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA before the end of the first quarter 2023.
  • In June 2021, FDA granted lecanemab Breakthrough Therapy designation and in December 2021, FDA granted lecanemab Fast track designation.
  • Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease.

Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway

Retrieved on: 
Tuesday, May 10, 2022
Development, University, Core, Biomarker, National Institute on Aging, Safety, Parkinson's disease, Caregiver, BAN2401, Pharmaceuticals and Medical Devices Agency, Person, Eisai, National, Medication, Ageing, CEO, Clarity, AD, Brain, CET, Patient, Partnership, Neurodegeneration, Clinical trial, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biologics license application, Disease, Research, Alzheimer's Research & Therapy, Medicines and Healthcare products Regulatory Agency, Priority review, AB, Commercialization, Nasdaq Stockholm, Degenerative disease, BLA, PMDA, National Institute, MCI, Prescription Drug User Fee Act, Nasdaq, Food, Amyloid, Biogen, ADAS, Marketing, PDUFA, Autumn, Pharmaceutical industry, Medical imaging, Medical device, EU, Alzheimer's disease, Uppsala University

While Eisai is currently submitting lecanemab under the accelerated approval pathway, the lecanemab Phase 3 confirmatory Clarity AD clinical trial conducted with 1,795 patients will report out in the Fall of 2022.

Key Points: 
  • While Eisai is currently submitting lecanemab under the accelerated approval pathway, the lecanemab Phase 3 confirmatory Clarity AD clinical trial conducted with 1,795 patients will report out in the Fall of 2022.
  • Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA before the end of the first quarter 2023.
  • In June 2021, FDA granted lecanemab Breakthrough Therapy designation and in December 2021, FDA granted lecanemab Fast track designation.
  • Collaborations with universities are of great importance to the company together with its strategically important global partner Eisai in Alzheimer disease.

Correction of press release: Missing MAR label in previous press release "RaySearch collaborates with GE Healthcare to improve radiation oncology treatment planning"

Retrieved on: 
Monday, May 9, 2022
People, Software, EU, Ecosystem, Proton, GE Healthcare, Nasdaq Stockholm, Carbon, MAR, RaySearch Laboratories, Karolinska Institute, TCS, NYSE, Neoplasm, Radiation, Oncology, NIH Public Access Policy, Patient, Caregiver, Ion, HDR, Hospital, Electron, Face, Photon, OIS, Thomas Edison, Solution, CEO, Technology, Helium, OAS, TPS, Medical device, Medical imaging, Pharmaceutical industry, Imaging, Cancer

The correction refers to the fact that the press release lacked the MAR label with reference to the EU Market Abuse Regulation (MAR).

Key Points: 
  • The correction refers to the fact that the press release lacked the MAR label with reference to the EU Market Abuse Regulation (MAR).
  • Jan Makela, President & CEO, Imaging, GE Healthcare, says: "GE Healthcare is delighted to be partnering with RaySearch, as we seek to improve precision guidance during radiation therapy planning and treatment.
  • Telephone: +46 (0)8 510 530 00, [email protected]
    GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).
  • RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch collaborates with GE Healthcare to improve radiation oncology treatment planning

Retrieved on: 
Monday, May 9, 2022
People, Software, Ecosystem, Proton, GE Healthcare, Nasdaq Stockholm, Carbon, RaySearch Laboratories, Karolinska Institute, TCS, NYSE, Neoplasm, Radiation, Oncology, NIH Public Access Policy, Patient, Caregiver, Ion, HDR, Hospital, Electron, Face, Photon, OIS, Thomas Edison, Solution, CEO, Technology, Helium, OAS, TPS, Medical imaging, Pharmaceutical industry, Imaging, Cancer

GE Healthcare and RaySearch aim to enable hospitals and cancer treatment centers to implement an interoperable and integrated workflow that will optimize their clinical planning and operational outcomes.

Key Points: 
  • GE Healthcare and RaySearch aim to enable hospitals and cancer treatment centers to implement an interoperable and integrated workflow that will optimize their clinical planning and operational outcomes.
  • As providers look to automate radiation oncology processes in the face of increasing numbers of patients and advancements in radiation treatment delivery procedures, GE and RaySearch are working to bring together complementary technologies and solutions in order to advance innovation and help the radiation oncology community.
  • Jan Makela, President & CEO, Imaging, GE Healthcare, says: "GE Healthcare is delighted to be partnering with RaySearch, as we seek to improve precision guidance during radiation therapy planning and treatment.
  • RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.